Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

The Adhesion Molecule Anosmin-1 in Neurology: Kallmann Syndrome and Beyond

  • Castro Soubriet, Fernando de
  • Esteban, Pedro F.
  • Bribián, Ana
  • Murcia-Belmonte, Verónica
  • García-González, Diego
  • Clemente, Diego
Anosmin-1 is the glycoprotein encoded by the KAL1 gene and part of the extracellular matrix, which was first identified as defective in human Kallmann syndrome (KS, characterised by hypogonadotropic hypogonadism and anosmia); biochemically it is a cell adhesion protein. The meticulous biochemical dissection of the anosmin-1 domains has identified which domains are necessary for the protein to bind its different partners to display its biological effects. Research in the last decade has unravelled different roles of anosmin-1 during CNS development (axon pathfinding, axonal collateralisation, cell motility and migration), some of them intimately related with the cited KS but not only with this. More recently, anosmin-1 has been identified in other pathological scenarios both within (multiple sclerosis) and outside (cancer, atopic dermatitis) the CNS., Our research is currently supported by grants from the Spanish Ministerio de Economía y Competitividad-MINECO (ADE10-0010, RD07-0060-2007, SAF2009-07842), and Fundación Eugenio Rodríguez Pascual (Spain) to FdC, Association pour la Recherche en Escleròse en Plaques-ARSEP (France) to DCL and FdC, and Gobierno de Castilla-La Mancha (PI2009/26 and PI2009/29,) to DCL and PFE, respectively. VMB is a PhD student who had a fellowship from Gobierno de Castilla-La Mancha (MOV2007-JI/19) and is currently hired under RD07-0060-2007. DGG is a PhD student who had a fellowship from Gobierno de Gastilla-La Mancha (PI2007-66) and is currently hired by SESCAM. DCL, FdCS and PFE are hired by SESCAM. ABA is the recipient of a Sara Borrell contract from the Spanish Ministerio de Economía y Competitividad-MINECO., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interleukin-6, a Major Cytokine in the Central Nervous System

  • Erta Cañabate, Maria
  • Quintana Romero, Albert|||0000-0003-1674-7160
  • Hidalgo Pareja, Juan|||0000-0003-0921-1122
Interleukin-6 (IL-6) is a cytokine originally identified almost 30 years ago as a B-cell differentiation factor, capable of inducing the maturation of B cells into antibody-producing cells. As with many other cytokines, it was soon realized that IL-6 was not a factor only involved in the immune response, but with many critical roles in major physiological systems including the nervous system. IL-6 is now known to participate in neurogenesis (influencing both neurons and glial cells), and in the response of mature neurons and glial cells in normal conditions and following a wide arrange of injury models. In many respects, IL-6 behaves in a neurotrophin-like fashion, and seemingly makes understandable why the cytokine family that it belongs to is known as neuropoietins. Its expression is affected in several of the main brain diseases, and animal models strongly suggest that IL-6 could have a role in the observed neuropathology and that therefore it is a clear target of strategic therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neurofilament light chain level is a weak risk factor for the development of MS

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Picón, Carmen
  • Kuhle, Jens|||0000-0002-6963-8892
  • Disanto, Giulio
  • Kappos, Ludwig|||0000-0003-4175-5509
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Pareto, Deborah|||0000-0001-7356-3769
  • Simon, Eva
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Río, Jordi|||0000-0003-4546-7627
  • Nos, Carlos|||0000-0002-3830-4910
  • Tur, Carmen|||0000-0003-1849-3184
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (r = -0.892) and percentage brain volume change (r = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Lesion topographies in multiple sclerosis diagnosis

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Tintoré, Mar|||0000-0001-9999-5359
  • Auger, Cristina|||0000-0001-9846-4767
  • Río, Jordi|||0000-0003-4546-7627
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Nos, Carlos|||0000-0002-3830-4910
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Mitjana, Raquel|||0000-0002-2076-9461
  • Mulero, Patricia|||0000-0001-8716-8997
  • de Barros, Andrea
  • Rodríguez Acevedo, Breogán|||0000-0002-0314-753X
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
To assess the contributions of cortico-juxtacortical and corpus callosum lesions to multiple sclerosis diagnosis and to compare the value of ≥1 vs ≥3 periventricular lesions in clinically isolated syndromes (CIS). Step 1: We evaluated lesion topography classifications in 657 patients with CIS with stepwise Cox proportional hazards regression models considering second attack as the outcome. Step 2: We established 2 dissemination in space (DIS) versions according to the periventricular lesion cutoffs of ≥1 and ≥3 and assessed their performance at 10 years with second attack as the outcome, first individually and then combined with dissemination in time (DIT) in all cases (n = 326), by age, and by CIS topography. Step 1: The models (hazard ratios [95% confidence interval]) favored ≥1 over ≥3 periventricular lesions (2.5 [1.7-3.6]) and cortico-juxtacortical over juxtacortical lesions (1.4 [1.0-1.8]). Callosal lesions were not selected. Step 2: DIS specificity with ≥1 periventricular lesions was slightly lower than with ≥3 (59.1 vs 61.4) and the same after adding DIT (88.6). Regarding age, ≥3 periventricular lesions improved DIS specificity over ≥1 lesions in the 40-49 years of age bracket (66.7 vs 58.3). This difference disappeared when adding DIT (83.3). Optic neuritis had a similar pattern when evaluating CIS topographies. Our results comply with the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) consensus recommendation of combining cortical and juxtacortical lesions into a single term when possible. Concerning periventricular lesions, maintaining the current ≥1 cutoff in the McDonald criteria does not compromise specificity in typical CIS cases, but attention should be paid to older patients or optic neuritis cases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE

  • Marín, Nieves
  • Mecha, Miriam
  • Espejo, Carmen|||0000-0001-9949-5901
  • Mestre, Leyre|||0000-0001-6970-2316
  • Eixarch, Herena|||0000-0001-7525-9533
  • Montalban, Xavier|||0000-0002-0098-9918
  • Alvarez-Cermeño, José C|||0000-0002-1345-2837
  • Guaza, Carmen|||0000-0003-3240-9807
  • Villar, Luisa M.|||0000-0002-9067-3668
Background and Objectives. Resistant and susceptible mouse strains to experimental autoimmune encephalomyelitis (EAE), an inducible demyelinating experimental disease serving as animal model for multiple sclerosis, have been described. We aimed to explore MHC-independent mechanisms inducing resistance to EAE. Methods. For EAE induction, female C57BL/6 (susceptible strain) and CD1 (resistant outbred strain showing heterogeneous MHC antigens) mice were immunized with the 35-55 peptide of myelin oligodendrocyte glycoprotein (MOG). We studied T cell proliferation, regulatory and effector cell subpopulations, intracellular and serum cytokine patterns, and titers of anti-MOG serum antibodies. Results. Upon immunization with MOG, T lymphocytes from susceptible mice but not that of resistant strain were capable of proliferating when stimulated with MOG. Accordingly, resistant mice experienced a rise in regulatory B cells (P = 0.001) and, to a lower extent, in regulatory T cells (P = 0.02) compared with C57BL/6 susceptible mice. As a consequence, MOG-immunized C57BL/6 mice showed higher percentages of CD4+ T cells producing both IFN-gamma (P = 0.02) and IL-17 (P = 0.009) and higher serum levels of IL-17 (P = 0.04) than resistant mice. Conclusions. Expansion of regulatory B and T cells contributes to the induction of resistance to EAE by an MHC-independent mechanism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum Biomarker gMS-Classifier2, Predicting Conversion to Clinically Definite Multiple Sclerosis

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Yarden, Jennifer
  • Fire, Ella
  • Spector, Larissa
  • Dotan, Nir
  • Dukler, Avinoam
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
Anti-glycan antibodies can be found in autoimmune diseases. IgM against glycan P63 was identified in clinically isolated syndromes (CIS) and included in gMS-Classifier2, an algorithm designed with the aim of identifying patients at risk of a second demyelinating attack. To determine the value of gMS-Classifier2 as an early and independent predictor of conversion to clinically definite multiple sclerosis (CDMS). Data were prospectively acquired from a CIS cohort. gMS-Classifier2 was determined in patients first seen between 1995 and 2007 with ≥ two 200 µL serum aliquots (N = 249). The primary endpoint was time to conversion to CDMS at two years, the factor tested was gMS-Classifier2 status (positive/negative) or units; other exploratory time points were 5 years and total time of follow-up. Seventy-five patients (30.1%) were gMS-Classifier2 positive. Conversion to CDMS occurred in 31/75 (41.3%) of positive and 45/174 (25.9%) of negative patients (p = 0.017) at two years. Median time to CDMS was 37.8 months (95% CI 10.4-65.3) for positive and 83.9 months (95% CI 57.5-110.5) for negative patients. gMS-Classifier2 status predicted conversion to CDMS within two years of follow-up (HR = 1.8, 95% CI 1.1-2.8; p = 0.014). gMS-Classifier2 units were also independent predictors when tested with either Barkhof criteria and OCB (HR = 1.2, CI 1.0-1.5, p = 0.020) or with T2 lesions and OCB (HR = 1.3, CI 1.1-1.5, p = 0.008). Similar results were obtained at 5 years of follow-up. Discrimination measures showed a significant change in the area under the curve (ΔAUC) when adding gMS-Classifier2 to a model with either Barkhof criteria (ΔAUC 0.0415, p = 0.012) or number of T2 lesions (ΔAUC 0.0467, p = 0.009), but not when OCB were added to these models. gMS-Classifier2 is an independent predictor of early conversion to CDMS and could be of clinical relevance, particularly in cases in which OCB are not available
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

  • Alcina, Antonio|||0000-0001-7294-0948
  • Fedetz, Maria
  • Fernández Fernández, Óscar|||0000-0003-3696-789X
  • Saiz, Albert|||0000-0002-5793-8791
  • Izquierdo, Guillermo|||0000-0002-6340-5609
  • Lucas, Miguel
  • Leyva, Laura|||0000-0003-0620-9625
  • García-León, Juan Antonio
  • Abad-Grau, María del Mar
  • Alloza, Iraide
  • Antigüedad, Alfredo
  • Garcia-Barcina, María J.
  • Vandenbroeck, Koen|||0000-0002-6967-6485
  • Varadé, Jezabel
  • de la Hera, Belén
  • Arroyo, Rafael
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montalban, Xavier|||0000-0002-0098-9918
  • Petit Marty, Natalia Paola|||0000-0002-3810-1152
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Otaegui, David|||0000-0002-6625-5976
  • Olascoaga, Javier
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Urcelay, Elena|||0000-0001-8470-8396
  • Matesanz, Fuencisla|||0000-0002-9429-1819
Background and aim: Several studies have highlighted the association of the 12q13.3-12q14.1 region with coeliac disease, type 1 diabetes, rheumatoid arthritis and multiple sclerosis (MS); however, the causal variants underlying diseases are still unclear. The authors sought to identify the functional variant of this region associated with MS. Methods: Tag-single nucleotide polymorphism (SNP) analysis of the associated region encoding 15 genes was performed in 2876 MS patients and 2910 healthy Caucasian controls together with expression regulation analyses. Results: rs6581155, which tagged 18 variants within a region where 9 genes map, was sufficient to model the association. This SNP was in total linkage disequilibrium (LD) with other polymorphisms that associated with the expression levels of FAM119B, AVIL, TSFM, TSPAN31 and CYP27B1 genes in different expression quantitative trait loci studies. Functional annotations from Encyclopedia of DNA Elements (ENCODE) showed that six out of these rs6581155-tagged-SNPs were located in regions with regulatory potential and only one of them, rs10877013, exhibited allele-dependent (ratio A/G=9.5-fold) and orientation-dependent (forward/reverse=2.7-fold) enhancer activity as determined by luciferase reporter assays. This enhancer is located in a region where a long-range chromatin interaction among the promoters and promoter-enhancer of several genes has been described, possibly affecting their expression simultaneously. Conclusions: This study determines a functional variant which alters the enhancer activity of a regulatory element in the locus affecting the expression of several genes and explains the association of the 12q13.3-12q14.1 region with MS.